ArticleInternational journal of molecular sciences2026
Ameliorative Effects of Citrus Unshiu Peel Extract in Cellular and Mouse Models of Pelizaeus-Merzbacher Disease.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hypomyelinating leukodystrophy 1 (HLD1), also known as Pelizaeus-Merzbacher disease (PMD), is a severe X-linked hereditary hypomyelinating/demyelinating disorder caused primarily by genomic duplications or multiplications that lead to the increased expression of proteolipid protein 1 (PLP1). Aberrant PLP1 expression impairs oligodendrocyte differentiation and disrupts myelin formation in the central nervous system (CNS). Despite decades of research, effective disease-modifying therapies remain unavailable. In the present study, we investigated the potential of Chinpi, the Citrus Unshiu Peel extract commonly utilized in traditional herbal medicine and reported to protect cells from various cellular stresses, using both in vitro cellular and in vivo animal models of PMD. Using an FBD-102b oligodendrocyte precursor model cell line engineered to overexpress PLP1, we demonstrated that treatment with Chinpi significantly ameliorates critical defects in morphological differentiation and successfully restores the expression of major myelin proteins. Furthermore, oral administration of Chinpi to PLP1 transgenic mice improves myelin protein expression in the brain and significantly alleviates progressive motor incoordination, as assessed by behavioral tests. Taken together, these findings suggest that Chinpi exerts protective effects against PLP1-induced morphological differentiation defects and subsequent reductions in myelin protein expression, highlighting its potential as a recovery approach for PMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.